Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs.

MLA

Minosse, Claudia, et al. “Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs.” Viruses (1999-4915), vol. 13, no. 6, June 2021, p. 1151. EBSCOhost, https://doi.org/10.3390/v13061151.

APA

Minosse, C., Gruber, C. E. M., Rueca, M., Taibi, C., Zaccarelli, M., Grilli, E., Montalbano, M., Capobianchi, M. R., Antinori, A., D’Offizi, G., McPhee, F., & Garbuglia, A. R. (2021). Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs. Viruses (1999-4915), 13(6), 1151. https://doi.org/10.3390/v13061151

Chicago

Minosse, Claudia, Cesare E. M. Gruber, Martina Rueca, Chiara Taibi, Mauro Zaccarelli, Elisabetta Grilli, Marzia Montalbano, et al. 2021. “Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs.” Viruses (1999-4915) 13 (6): 1151. doi:10.3390/v13061151.